This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Testing Strategies to Improving Warfarin Adherence

This study has been completed.
Aetna, Inc.
Information provided by:
University of Pennsylvania Identifier:
First received: January 15, 2008
Last updated: December 1, 2009
Last verified: December 2009
We are performing a research study to learn more about the control of an individual's blood thinning (anticoagulation) on warfarin. Individuals from an anticoagulation clinic are being asked to participate in order to see if a lottery which provides the opportunity to win money in combination with the use of the Med-eMonitor might be useful in helping patients to achieve better control of their anticoagulation therapy. Half of the participants will be enrolled in the lottery arm and the other half will be a control group who will receive the Med-eMonitor only.

Condition Intervention
Atrial Fibrillation Deep Venous Thrombosis Dilated Cardiomyopathies Behavioral: Lottery arm (Lottery and Med-eMonitor) Behavioral: Non-Lottery (Med-eMonitor only)

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Health Services Research
Official Title: Testing Strategies to Improving Warfarin Adherence

Resource links provided by NLM:

Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • anticoagulation control [ Time Frame: six months ]

Secondary Outcome Measures:
  • adherence [ Time Frame: six months ]

Enrollment: 101
Study Start Date: December 2007
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
50% of the consenting subjects will take part in the lottery and use the Med-eMonitor as a device to monitor adherence
Behavioral: Lottery arm (Lottery and Med-eMonitor)
Lottery and Med-eMonitor
50% of the consenting subjects will use only the Med-eMonitor as a device to monitor adherence
Behavioral: Non-Lottery (Med-eMonitor only)
Med-eMonitor only


Ages Eligible for Study:   21 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 21 years old age or older
  • On warfarin managed at the AC clinic
  • Target INR 2.0-3.0 or 2.5-3.5
  • At maintenance phase of therapy (defined as stable INR with stable warfarin dosing over at least 2 consecutive visits)

Exclusion Criteria:

  • Do not have access to telephone line
  • Unwillingness to participate or to sign a consent form(refusal)
  • Inability to participate because of advances dementia, advanced Alzheimer's disease or other impairment affecting ability to provide informed consent and/or quality data or utilize the Med-eMonitor
  • Participation in a current study that does not permit participation in another study
  • End stage or terminal illness with anticipated life expectancy of 6 months or less
  • INR over the upper limit for the individual's range at the time of enrollment (e.g.,>3.0 or >3.5, depending on the target range)
  • Diagnosed with antiphospholipid antibody syndrome or abnormal INR prior to starting warfarin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00622102

United States, Pennsylvania
Hospital of the University of Pennsylvania Anticoagulation Management Center
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
Aetna, Inc.
Principal Investigator: Kevin G Volpp, M.D., Ph.D. University of Pennsylvania
  More Information

Responsible Party: Stephen E. Kimmel, M.D., M.S.C.E., University of Pennsylvania School of Medicine Identifier: NCT00622102     History of Changes
Other Study ID Numbers: 806634
Study First Received: January 15, 2008
Last Updated: December 1, 2009

Keywords provided by University of Pennsylvania:
Mechanical heart valves

Additional relevant MeSH terms:
Atrial Fibrillation
Venous Thrombosis
Cardiomyopathy, Dilated
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes
Embolism and Thrombosis
Vascular Diseases
Anticoagulants processed this record on June 23, 2017